Use of Indocyanine Green Cholangiography and Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy (CAMFIB)
Primary Purpose
Liver Disease
Status
Unknown status
Phase
Phase 3
Locations
France
Study Type
Interventional
Intervention
indocyanine green fluorescent cholangiography
methylene blue
Sponsored by
About this trial
This is an interventional diagnostic trial for Liver Disease focused on measuring per operative cholangiography, liver resection, biliary fistula
Eligibility Criteria
Inclusion Criteria:
- benin or malignant liver disease with resection of 2 or more segments
- liver resection by laparotomy
- written consent
Exclusion Criteria:
- previous hepatectomy
- emergency surgery
- allergy to indocyanine green
- allergy to methylene blue
- pregnancy or breastfeeding
Sites / Locations
- Amiens University HospitalRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Experimental
Active Comparator
Arm Label
indocyanine green fluorescent cholangiography
methylene blue
Arm Description
use of indocyanine green fluorescent cholangiography in the patients of this arm, an indocyanine green fluorescent cholangiography is performed
injection of methylene blue during the surgery
Outcomes
Primary Outcome Measures
biliary fistula rate
the biliary fistula is defined as a bilirubin in the drain three times higher than the serum bilirubin.
the primary endpoint will be evaluated by a medical committee composed by investigators not involved in the patients enrollment.
Secondary Outcome Measures
Full Information
NCT ID
NCT01847612
First Posted
April 30, 2013
Last Updated
August 20, 2018
Sponsor
Centre Hospitalier Universitaire, Amiens
1. Study Identification
Unique Protocol Identification Number
NCT01847612
Brief Title
Use of Indocyanine Green Cholangiography and Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy
Acronym
CAMFIB
Official Title
Evaluation of Indocyanine Green Fluorescent Cholangiography Versus Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy: Randomized Controlled Study
Study Type
Interventional
2. Study Status
Record Verification Date
August 2018
Overall Recruitment Status
Unknown status
Study Start Date
July 8, 2013 (Actual)
Primary Completion Date
August 2018 (Anticipated)
Study Completion Date
August 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Centre Hospitalier Universitaire, Amiens
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
The aim of the present study is to evaluate whether the use of indocyanine green fluorescent cholangiography is responsible in a decrease of biliary fistula's rate in patients with liver diseases requiring liver resection.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Liver Disease
Keywords
per operative cholangiography, liver resection, biliary fistula
7. Study Design
Primary Purpose
Diagnostic
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
132 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
indocyanine green fluorescent cholangiography
Arm Type
Experimental
Arm Description
use of indocyanine green fluorescent cholangiography in the patients of this arm, an indocyanine green fluorescent cholangiography is performed
Arm Title
methylene blue
Arm Type
Active Comparator
Arm Description
injection of methylene blue during the surgery
Intervention Type
Procedure
Intervention Name(s)
indocyanine green fluorescent cholangiography
Intervention Type
Drug
Intervention Name(s)
methylene blue
Primary Outcome Measure Information:
Title
biliary fistula rate
Description
the biliary fistula is defined as a bilirubin in the drain three times higher than the serum bilirubin.
the primary endpoint will be evaluated by a medical committee composed by investigators not involved in the patients enrollment.
Time Frame
postoperative week 4
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
benin or malignant liver disease with resection of 2 or more segments
liver resection by laparotomy
written consent
Exclusion Criteria:
previous hepatectomy
emergency surgery
allergy to indocyanine green
allergy to methylene blue
pregnancy or breastfeeding
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
jean marc regimbeau, MD, phD
Phone
+33 3 22 66 83 00
Email
regimbeau.jean-marc@chu-amiens.fr
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
jean marc regimbeau, MD, PhD
Organizational Affiliation
CHU amiens
Official's Role
Principal Investigator
Facility Information:
Facility Name
Amiens University Hospital
City
Amiens
Country
France
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
jean marc regimbeau, MD, PhD
Phone
+33 3 22 66 83 00
Email
regimbeau.jean-marc@chu-amiens.fr
12. IPD Sharing Statement
Citations:
PubMed Identifier
23533786
Citation
Nguyen-Khac E, Lobry C, Chatelain D, Fuks D, Joly JP, Brevet M, Tramier B, Mouly C, Hautefeuille V, Chauffert B, Regimbeau JM. A Reappraisal of Chemotherapy-Induced Liver Injury in Colorectal Liver Metastases before the Era of Antiangiogenics. Int J Hepatol. 2013;2013:314868. doi: 10.1155/2013/314868. Epub 2013 Mar 7.
Results Reference
background
Learn more about this trial
Use of Indocyanine Green Cholangiography and Methylene Blue to Detect Postoperative Biliary Fistula After Hepatectomy
We'll reach out to this number within 24 hrs